Critical Review: GeneDx (NASDAQ:WGS) vs. Ryman Healthcare (OTCMKTS:RYHTY)

GeneDx (NASDAQ:WGS) and Ryman Healthcare (OTCMKTS:RYHTY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Profitability

This table compares GeneDx and Ryman Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	0.39%	16.51%	9.35%
Ryman Healthcare	N/A	N/A	N/A

Earnings and Valuation

This table compares GeneDx and Ryman Healthcare”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$305.45 million	11.38	-$52.29 million	$0.05	2,420.20
Ryman Healthcare	$451.64 million	N/A	-$259.39 million	N/A	N/A

GeneDx has higher earnings, but lower revenue than Ryman Healthcare.

Analyst Recommendations

This is a breakdown of current ratings and target prices for GeneDx and Ryman Healthcare, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	3	8	0	2.58
Ryman Healthcare	0	0	0	0	0.00

GeneDx currently has a consensus price target of $112.80, indicating a potential downside of 6.78%. Given GeneDx’s stronger consensus rating and higher probable upside, equities research analysts plainly believe GeneDx is more favorable than Ryman Healthcare.

Institutional & Insider Ownership

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

GeneDx has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Ryman Healthcare has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Summary

GeneDx beats Ryman Healthcare on 10 of the 11 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About Ryman Healthcare

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The company's villages provide a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which offers rest homes, hospitals, dementia-level care, and respite and day care services. Its villages also provide all-weather bowling green, indoor heated swimming pool and spa, gym, internal atrium, beauty and hair salons, library, dining area, bar, lounges, croquet laws, shops, and movie theatre facilities. The company owns and operates retirement village units and care units. The company was founded in 1984 and is based in Christchurch, New Zealand.